Healthcare -
Biotechnology - NASDAQ - US
$ 2.92
4.29 %
$ 2.21 M
Market Cap
-0.01
P/E
1. INTRINSIC VALUE
2. FUNDAMENTAL
ANALYSIS
Price Chart CDT
FINANCIALS
Balance Sheet
Conduit Pharmaceuticals Inc.
| Current Assets | 2.72 M |
| Cash & Short-Term Investments | 554 K |
| Receivables | 489 K |
| Other Current Assets | 1.67 M |
| Non-Current Assets | 1.48 M |
| Long-Term Investments | 0 |
| PP&E | 303 K |
| Other Non-Current Assets | 1.18 M |
| Current Liabilities | 10.7 M |
| Accounts Payable | 1.43 M |
| Short-Term Debt | 7.23 M |
| Other Current Liabilities | 2.08 M |
| Non-Current Liabilities | 245 K |
| Long-Term Debt | 107 K |
| Other Non-Current Liabilities | 138 K |
EFFICIENCY
Earnings Waterfall
Conduit Pharmaceuticals Inc.
| Revenue | 922 M |
| Cost Of Revenue | 0 |
| Gross Profit | 922 M |
| Operating Expenses | 15.4 M |
| Operating Income | 266 M |
| Other Expenses | 284 M |
| Net Income | -17.8 M |
RATIOS
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis
Conduit Pharmaceuticals Inc.
| Net Income | -17.8 M |
| Depreciation & Amortization | 457 K |
| Capital Expenditures | -51 K |
| Stock-Based Compensation | 1.63 M |
| Change in Working Capital | -142 K |
| Others | 4.81 M |
| Free Cash Flow | -9.73 M |
Wall Street Analysts Price Targets
Conduit Pharmaceuticals Inc.
CDT has no price targets from Wall Street.
4. DIVIDEND
ANALYSIS
CDT does not distribute dividends.
5. COMPETITION
6. Ownership
Insider Ownership
Conduit Pharmaceuticals Inc.
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
4.58 M USD 2
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
7. News
CDT Environmental Technology Announces Receipt of Notification Letter from Nasdaq
SHENZHEN, China, June 20, 2025 (GLOBE NEWSWIRE) -- CDT Environmental Technology Investment Holdings Limited (NASDAQ:CDTG) (“CDT” or the “Company”), a leading provider of waste treatment systems and services throughout China, today announced that it received a notification letter, dated June 18, 2025 (the “Notification Letter”), from the Listing Qualifications Department of The Nasdaq Stock Market Inc. (“Nasdaq”) indicating that the Company is no longer in compliance with the minimum bid price requirement set forth in Nasdaq Listing Rule 5550(a)(2) as the Company's closing bid price per ordinary share, par value US$0.0025 per share, was below US$1.00 for a period of 30 consecutive business days. The Notification Letter does not result in the immediate delisting of the Company's securities.
globenewswire.com
- 4 weeks ago
Conduit Pharmaceuticals Enters Joint Development Agreement with Manoira to Advance AZD1656 and AZD5658 in Animal Health
Collaboration leverages cutting-edge reformulation expertise to generate cross-species insights, fast-track human clinical programs, and seeks to capture commercial potential in the $15 billion animal health market Evaluation of AZD5658 expands Conduit's glucokinase activator platform into novel veterinary applications, complementing AZD1656 development Cost-efficient approach enhances Conduit's pipeline while preserving full ownership of intellectual property and data, maximizing shareholder value Synergistic combination therapies under evaluation could redefine treatment standards in veterinary and human applications NAPLES, Fla. and CAMBRIDGE, United Kingdom, June 04, 2025 (GLOBE NEWSWIRE) -- Conduit Pharmaceuticals Inc. (Nasdaq: CDT) (“Conduit” or the “Company”) today announced that it has entered into a joint development agreement with Manoira Corporation (“Manoira”), a privately held specialty animal health company specializing in proprietary reformulation technologies to create novel therapeutics for veterinary and livestock applications.
globenewswire.com
- 1 month ago
Conduit Pharmaceuticals Inc. Listing on Nasdaq Capital Market
NAPLES, Fla. and CAMBRIDGE, United Kingdom, May 22, 2025 (GLOBE NEWSWIRE) -- Conduit Pharmaceuticals Inc. (Nasdaq: CDT) (“Conduit” or the “Company”), a dynamic, multi-asset clinical stage, life science company delivering an efficient model for compound development, announces that, following confirmation of compliance with the Bid Price and Equity Requirements as detailed in the announcement dated May 21, 2025, the Company received formal notice from The Nasdaq Stock Market LLC (“Nasdaq”) that the Company's application to transfer the listing of its common stock to The Nasdaq Capital Market has been approved and the Company's securities will be transferred to The Nasdaq Capital Market at the opening of business on May 23, 2025.
globenewswire.com
- 1 month ago
Conduit Pharmaceuticals Inc. Regains Nasdaq Compliance
Conduit regains compliance with Bid Price and Equity Requirements CDT will continue to be listed and traded on The Nasdaq Stock Market NAPLES, Fla. and CAMBRIDGE, United Kingdom, May 21, 2025 (GLOBE NEWSWIRE) -- Conduit Pharmaceuticals Inc. (Nasdaq: CDT) (“Conduit” or the “Company”), a dynamic, multi-asset clinical stage, life science company delivering an efficient model for compound development, announced that the Company received formal notice from The Nasdaq Stock Market LLC (“Nasdaq”) that the Company has regained compliance with Nasdaq's minimum bid price requirement (the “Bid Price Requirement”) set forth in Nasdaq Listing Rule 5550(a)(2), as well as Nasdaq's stockholders' equity requirement (“Equity Requirement”) set forth in Nasdaq Listing Rule 5550(b)(1).
globenewswire.com
- 1 month ago
Conduit Pharmaceuticals Inc. Announces Reverse Stock Split
NAPLES, Fla. and CAMBRIDGE, United Kingdom, May 16, 2025 (GLOBE NEWSWIRE) -- Conduit Pharmaceuticals Inc. (Nasdaq: CDT) (“Conduit” or the “Company”), a dynamic, multi-asset clinical stage, life science company delivering an efficient model for compound development, announces that its board of directors has approved a 1-for-15 reverse stock split of the Company's common stock.
globenewswire.com
- 2 months ago
CDT Environmental Technology Files Annual Report on Form 20-F
Revenue of $29.8 million and net income of $1.4 million impacted by reduced project activity due to a slowdown in the PRC economy Revenue of $29.8 million and net income of $1.4 million impacted by reduced project activity due to a slowdown in the PRC economy
globenewswire.com
- 2 months ago
Conduit Pharmaceuticals Receives Further Patent Approval For Its Lead Asset Targeting Autoimmune Diseases
Conduit secures a composition of matter patent from the Korean Intellectual Property Office for its lead asset, AZD1656, a Glucokinase Activator targeting autoimmune disorders, positioning the Company for clinical development and strategic partnerships. NAPLES, Fla.
globenewswire.com
- 2 months ago
Conduit Pharmaceuticals Files Composition of Matter Patent for AZD5904 Creating Robust IP Foundation for Pipeline Asset
New patent filing secures composition of matter protection for AZD5904, a potent myeloperoxidase inhibitor in Conduit's pipeline, unlocking up to 20 years of new IP runway and enabling enhanced formulation strategies to target a broad range of diseases. NAPLES, Fla.
globenewswire.com
- 2 months ago
Conduit Pharmaceuticals Announces Leadership Changes
NAPLES, Fla. and CAMBRIDGE, United Kingdom, April 16, 2025 (GLOBE NEWSWIRE) -- Conduit Pharmaceuticals Inc. (Nasdaq: CDT) ("Conduit Pharmaceuticals" or "Conduit" or the "Company") today announced key leadership changes to support the company's next phase of growth and execution.
globenewswire.com
- 3 months ago
Conduit Pharmaceuticals Announces Novel Cocrystal Patent Filing For VTAMA® (tapinarof) with Enhanced Therapeutic and Market Extension Prospects
Conduit Pharmaceuticals files next generation cocrystal patent for VTAMA ® (tapinarof) which the Company believes could be a superior asset with both inflammatory and autoimmune prospectives just as the drug approaches 2027 exclusivity expiration, positioning the Company for high-value licensing partnerships. NAPLES, Fla.
globenewswire.com
- 3 months ago
Conduit Pharmaceuticals Receives U.S. Patent Approval For Its Lead Asset Targeting Autoimmune Diseases
Conduit secures a composition of matter patent from the USPTO for its lead asset, AZD1656, a Glucokinase Activator targeting autoimmune disorders, positioning the Company for clinical development and strategic partnerships. NAPLES, Fla.
globenewswire.com
- 3 months ago
Conduit Pharmaceuticals Provides Research and Development Update on Progress for Pipeline Assets AZD1656, AZD5658, and AZD5904
Conduit Pharmaceuticals advances its pipeline with key progress in preclinical lupus studies for AZD5658, Phase IIa trial design for AZD1656, formulation optimization, and IP expansion, positioning the Company for near-term milestones and growth. NAPLES, Fla.
globenewswire.com
- 4 months ago
8. Profile
Summary
Conduit Pharmaceuticals Inc. CDT
COUNTRY
US
INDUSTRY
Biotechnology
MARKET CAP
$ 2.21 M
Dividend Yield
0.43%
Description
Conduit Pharmaceuticals Inc. operates as a clinical stage specialty biopharmaceutical company that provides unmet medical needs in the areas of autoimmune disease and idiopathic male infertility. It's pipeline includes AZD1656 for the treatment of hashimoto's thyroiditis, renal transplant, uveitis, and preterm labor; and AZD5904 for the treatment of idiopathic male infertility. The company was founded in 2019 and is based in San Diego, California. Conduit Pharmaceuticals Limited is a subsidiary of Corvus Capital Limited.
Contact
4995 Murphy Canyon Road, San Diego, CA, 92134
https://www.conduitpharma.com
IPO
Date
March 28, 2022
Employees
6
Officers
Mr. James Bligh
Interim Chief Financial Officer & Director
Dr. David Joszef Tapolczay
Head of Strategy & Licensing
Dr. Joanne M. Holland
Chief Scientific Officer
Dr. Andrew Regan
Founder, Chief Executive Officer & Director